Serum Protein Profiles in Myasthenia Gravis

Annals of Thoracic Surgery

Volumn 88, Issue 4, 2009, Pages 1118-1123

  Cheng, Chao ^a   Wu, Guoyong ^a   Yeung, Sai Ching J ^d   Li, Rong ^b   Bella, Amos Ela ^a   Pang, Jinzhuo ^a   Zhong, Fo tian ^a   Luo, Honghe ^a   Jin, Yanli ^c   Pan, Jingxuan ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DECISION TREE; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECOVERIN; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYMECTOMY; YOUNG ADULT;

EID: 70249102463     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.05.032     Document Type: Article

References (22)

1. Juel V.C., and Massey J.M. Myasthenia gravis. Orphanet J Rare Dis 2 (2007) 44
2. Jaretzki III A., Barohn R.J., Ernstoff R.M., et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
3. Han K.Q., Huang G., Gao C.F., et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31 (2008) 133-139
4. Jansen C., Hebeda K.M., Linkels M., et al. Protein profiling of B-cell lymphomas using tissue biopsies: a potential tool for small samples in pathology. Cell Oncol 30 (2008) 27-38
5. Cazares L.H., Diaz J.I., Drake R.R., and Semmes O.J. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol Biol 428 (2008) 125-140
6. Osserman K.E., and Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38 (1971) 497-537
7. Robertson D.N. Enumerating neurology. Brain 123 (2000) 663-664
8. Yu Y.L., Hawkins B.R., Ip M.S., Wong V., and Woo E. Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease. Acta Neurol Scand 86 (1992) 113-119
9. Monden Y., Nakahara K., Kagotani K., et al. Effects of preoperative duration of symptoms on patients with myasthenia gravis. Ann Thorac Surg 38 (1984) 287-291
10. Kim H.K., Park M.S., Choi Y.S., et al. Neurologic outcomes of thymectomy in myasthenia gravis: comparative analysis of the effect of thymoma. J Thorac Cardiovasc Surg 134 (2007) 601-607
11. Xiao Z., Adam B.L., Cazares L.H., et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61 (2001) 6029-6033
12. Cazares L.H., Adam B.L., Ward M.D., et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 8 (2002) 2541-2552
13. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
14. Bichsel V.E., Liotta L.A., and Petricoin III E.F. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7 (2001) 69-78
15. Cui L.Y., Guan Y.Z., Wang H., and Tang X.F. Single fiber electromyography in the diagnosis of ocular myasthenia gravis: report of 90 cases. Chin Med J (Engl) 117 (2004) 848-851
16. Vincent A., McConville J., Farrugia M.E., and Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 24 (2004) 125-133
17. Wadsworth J.T., Somers K.D., Stack Jr. B.C., et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 130 (2004) 98-104
18. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2 (2002) 797-804
19. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18 (2005) 519-525
20. Leite M.I., Jacob S., Viegas S., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131 (2008) 1940-1952
21. Vandiedonck C., Giraud M., and Garchon H.J. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 25 suppl (2005) 6-11
22. Shrager J.B., Nathan D., Brinster C.J., et al. Outcomes after 151 extended transcervical thymectomies for myasthenia gravis. Ann Thorac Surg 82 (2006) 1863-1869